drugset / Trial / NCT00333385
Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
Phase 4
Terminated
120 enrolled
Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Baxter Healthcare Corporation · collabGlaxoSmithKline · collabRoche Pharma AG · collabVaincre la Mucoviscidose · collab
RandomizedCrossoverOpen-labelTreatment
Summary
The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
Timeline
- Start
- 2001-10
- Primary completion
- —
- Completion
- 2004-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceftazidime | Small molecule | 200 mg/kg | Intravenous |